Beyond Air appoints Jeff Myers, M.D., Ph.D. as Chief Medical Officer effective March 27, 2023

Beyond Air, Inc.

Dr. Myers brings ~15 years of biopharmaceutical executive experience and was previously a cardiothoracic surgeon at Massachusetts General Hospital.
Incumbent CMO Dr. Andrew Colin transitions to Senior Medical Director Global Clinical Leadership.
Dr. Myers received inducement option for 50,000 shares and inducement RSU for 50,000 shares, vesting over 4 and 5 years respectively.
Stock awards were approved by independent compensation committee under Nasdaq Listing Rule 5635(c)(4).
Beyond Air focuses on inhaled nitric oxide via LungFit platform for respiratory conditions and solid tumors through affiliate Beyond Cancer.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.